CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Guduchi Ghan VatiWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug564 COVID-19 patients Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D058070 Asymptomatic Diseases NIH 0.58

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients

Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear. Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.

NCT04480398 Covid19 Asymptomatic Condition Drug: Guduchi Ghan Vati
MeSH:Asymptomatic Diseases

Primary Outcomes

Description: Virologic clearance indicates the duration from the first Covid‐19 positive result to the first Covid-19 negative result

Measure: Virologic clearance

Time: 21 days

Secondary Outcomes

Description: change in the number of patients going from asymptomatic to moderately disease

Measure: Change in the number of patients going from asymptomatic to moderately disease

Time: 10-days of hospital admission

Description: Total duration of stay in hospital for complete recovery

Measure: Hospital Stay

Time: 21 days

Description: Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported)

Measure: Clinically relevant adverse effects

Time: 21-days


No related HPO nodes (Using clinical trials)